

NORTHERN TERRITORY OF AUSTRALIA

Poisons and Dangerous Drugs Act

NOTICE OF ISSUING AND PUBLICATION OF GUIDELINES

I, PETER HOWARD TOYNE, the Minister for Health, pursuant to section 31W(5) of the *Poisons and Dangerous Drugs Act* and with reference to section 8 of the *Interpretation Act*, give notice of the issuing of the Schedule 8 and Restricted Schedule 4 Substances Policy and Clinical Practice Guidelines published in the Schedule.

Dated *January 18* 2005.

Minister for Health

NORTHERN TERRITORY OF AUSTRALIA

Poisons and Dangerous Drugs Act

DECLARATION OF RESTRICTED SCHEDULE 8 SUBSTANCES

I, CHRISTINE ENID SELVEY, the Chief Health Officer, pursuant to section 31B of the *Poisons and Dangerous Drugs Act* and with reference to section 8 of the *Interpretation Act*, declare-

- (a) each Schedule 8 substance specified in the Schedule to be a restricted Schedule 8 substances: and
- (b) this declaration takes effect on 1 April 2006.

Dated *March 24* 2006.

Chief Health Officer

SCHEDULE

Suboxone 2mg in tablet form (buprenorphine 2mg/naloxone 0.5mg) for sublingual administration

Suboxone 8mg in tablet form (buprenorphine 8mg/naloxone 2mg) for sublingual administration

**Associations Incorporation Act
Section 54**

**NOTICE OF INTENTION TO TRANSFER PROPERTY
OF AN ASSOCIATION**

Toughlove NT Incorporated. NOTICE IS HEREBY GIVEN PURSUANT TO section 54(2) (b) of the said Act that in pursuance of a resolution of the above association passed on the 12th February 2005 it is the intention of the association to transfer all its property, both real and personal to Toughlove NSW Inc. on the expiration of twenty-eight days after the publication of this notice. Any member or creditor of the Association may within 28 days after the date of the publication of this notice, make application to the Supreme Court for an order prohibiting the proposed transfer of property.

Dated 23rd February 2005.

B. JESSEP
Public Officer.

1/26

Poisons and Dangerous Drugs Act

**DECLARATION OF EXEMPTION FROM
REQUIREMENT TO HOLD AUTHORISATION TO
SUPPLY RESTRICTED SCHEDULE 8 SUBSTANCES**

I, TARUN STEPHEN WEERAMANTHRI, the Chief Health Officer, pursuant to section 31P of the *Poisons and Dangerous Drugs Act*, exempt the class of medical practitioners specified in Schedule 1 from the requirement to hold an authorisation under section 31G of the Act to supply dexamphetamine and methylphenidate (restricted Schedule 8 substances) to a person subject to the conditions in Schedule 2.

Dated 14th June, 2005.

T. S. WEERAMANTHRI
Chief Health Officer

SCHEDULE 1

EXEMPT CLASS OF MEDICAL PRACTITIONERS

Medical practitioners who are locum paediatricians and paediatricians working in a group practice.

SCHEDULE 2

CONDITIONS OF EXEMPTION

1. Each exempt medical practitioner must hold an Authorisation to supply dexamphetamine or methylphenidate to at least one particular person receiving treatment in the group practice.
2. An exempt medical practitioner may supply dexamphetamine or methylphenidate to any person receiving treatment in the group practice-
 - (a) if the exempt medical practitioner holds an Authorisation to supply the substance to that particular person; or
 - (b) if any other exempt medical practitioner holds an Authorisation to supply the substance to that particular person.
3. The conditions of an Authorisation for the supply of dexamphetamine or methylphenidate to a particular person apply in relation to each exempt medical practitioner who supplies the substance to that person, whether or not the exempt medical practitioner holds the Authorisation.

4. In this Schedule-

"Authorisation" means an authorisation under section 31G of the *Poisons and Dangerous Drugs Act*;

"exempt medical practitioner" means a medical practitioner within the class referred to in Schedule 1.

2/26

**Poisons and Dangerous Drugs Act
Poisons and Dangerous Drugs Regulations
EXEMPTION**

I, TARUN STEPHEN WEERAMANTHRI, the Chief Health Officer, pursuant to regulation 4 of the Poisons and Dangerous Drugs Regulations, exempt a manufacturer of a Scheduled substance who has obtained exemption for a specified packaging or labelling requirement from another Australian jurisdiction from so much of Part 3 of the Regulations as is necessary to permit the packaging or labelling in the Territory of the Scheduled substance in accordance with the exemption obtained from that other jurisdiction.

Dated 14th June, 2005.

T. S. WEERAMANTHRI
Chief Health Officer

3/26

Place Names Act

NAMING OF PUBLIC PLACE


I, CHRISTOPHER BRUCE BURNS, the Minister for Lands and Planning, in pursuance of section 11 of the *Place Names Act*, approve the recommendation contained in a report by the Place Names Committee that the road shown bold on the plan appearing in the schedule be named Samuel Road, as indicated on that plan.

Dated 6th June, 2005.

C. B. BURNS
Minister for Lands
and Planning

NOTE:

SAMUEL ROAD is named after Samuel Beddington, a merchant of Hampstead, London, who, from 1871 until 1939, held the original titles to sections 449 and 450 through which this road passes.



4/26

Planning Act

**NOTICE OF MAKING OF AMENDMENT TO
PLANNING SCHEME
PALMERSTON TOWN PLAN 1982
(AMENDMENT NO. 140)**

NORTHERN TERRITORY OF AUSTRALIA

Poisons and Dangerous Drugs Act

DECLARATION OF RESTRICTED SCHEDULE 8 SUBSTANCES

I, TARUN STEPHEN WEERAMANTHRI, the Chief Health Officer, pursuant to section 31B of the *Poisons and Dangerous Drugs Act* and with reference to section 8 of the *Interpretation Act*, declare –

- (a) each Schedule 8 substance specified in the Schedule to be a restricted Schedule 8 substance; and
- (b) this declaration takes effect on 1 February 2005.

Dated 13th January 2005.

Chief Health Officer

SCHEDULE

Methadone in liquid form at strength 5mg/mL for oral administration
Buprenorphine in tablet form 0.4mg, 2mg or 8mg for sublingual administration

Dexamphetamine

Methylphenidate

NORTHERN TERRITORY OF AUSTRALIA

Poisons and Dangerous Drugs Act

DECLARATION OF EXEMPTION FROM REQUIREMENT
TO HOLD AUTHORISATION TO SUPPLY
RESTRICTED SCHEDULE 8 SUBSTANCES

I, TARUN STEPHEN WEERAMANTHRI, the Chief Health Officer, pursuant to section 31P of the *Poisons and Dangerous Drugs Act* and with reference to section 8 of the *Interpretation Act*, exempt the class of medical practitioners specified in Schedule 1 from the requirement to hold an authorisation under section 31G of the Act to supply methadone or buprenorphine (restricted Schedule 8 substances) to each particular person receiving treatment in the Alcohol and Other Drugs Service, subject to the conditions in Schedule 2.

Dated

13th January 2005.

Chief Health Officer

SCHEDULE 1

EXEMPT CLASS OF MEDICAL PRACTITIONERS
ALCOHOL AND OTHER DRUGS SERVICE

Medical practitioners who are employed by the Agency administering the *Poisons and Dangerous Drugs Act* to provide clinical services within the Alcohol and Other Drugs Service

SCHEDULE 2

CONDITIONS OF EXEMPTION ALCOHOL AND OTHER DRUGS SERVICE

1. Each exempt medical practitioner must hold an Authorisation to supply methadone or buprenorphine to at least one particular person receiving treatment in the Alcohol and Other Drugs Service.
2. An exempt medical practitioner may supply methadone or buprenorphine to any person receiving treatment in the Alcohol and Other Drugs Service --
 - (a) if the exempt medical practitioner holds an Authorisation to supply the substance to that particular person; or
 - (b) if any other exempt medical practitioner holds an Authorisation to supply the substance to that particular person.
3. The conditions of an Authorisation for the supply of methadone or buprenorphine to a particular person apply in relation to each exempt medical practitioner who supplies the substance to that person, whether or not the exempt medical practitioner holds the Authorisation.
4. In this Schedule --

"Authorisation" means an authorisation under section 31G of the *Poisons and Dangerous Drugs Act*,

"exempt medical practitioner" means a medical practitioner within the class referred to in Schedule 1.

NORTHERN TERRITORY OF AUSTRALIA

Poisons and Dangerous Drugs Act

DECLARATION OF EXEMPTION FROM REQUIREMENT
TO HOLD AUTHORISATION TO SUPPLY
RESTRICTED SCHEDULE 8 SUBSTANCES

I, TARUN STEPHEN WEERAMANTHRI, the Chief Health Officer, pursuant to section 31P of the *Poisons and Dangerous Drugs Act* and with reference to section 8 of the *Interpretation Act*, exempt the class of medical practitioners specified in Schedule 1 from the requirement to hold an authorisation under section 31G of the Act to supply methadone or buprenorphine (restricted Schedule 8 substances) to each particular person receiving treatment in the Alcohol and Other Drugs Service Central Australia, subject to the conditions in Schedule 2.

Dated

13th January

2005.

Chief Health Officer

SCHEDULE 1

EXEMPT CLASS OF MEDICAL PRACTITIONERS
ALCOHOL AND OTHER DRUGS SERVICE CENTRAL AUSTRALIA

Medical practitioners who are employed by the Agency administering the *Poisons and Dangerous Drugs Act* to provide clinical services within the Alcohol and Other Drugs Service Central Australia

SCHEDULE 2

CONDITIONS OF EXEMPTION

ALCOHOL AND OTHER DRUGS SERVICE CENTRAL AUSTRALIA

1. Each exempt medical practitioner must hold an Authorisation to supply methadone or buprenorphine to at least one particular person receiving treatment in the Alcohol and Other Drugs Service Central Australia.
2. An exempt medical practitioner may supply methadone or buprenorphine to any person receiving treatment in the Alcohol and Other Drugs Service Central Australia –
 - (a) if the exempt medical practitioner holds an Authorisation to supply the substance to that particular person; or
 - (b) if any other exempt medical practitioner holds an Authorisation to supply the substance to that particular person.
3. The conditions of an Authorisation for the supply of methadone or buprenorphine to a particular person apply in relation to each exempt medical practitioner who supplies the substance to that person, whether or not the exempt medical practitioner holds the Authorisation.
4. In this Schedule –

"Authorisation" means an authorisation under section 31G of the *Poisons and Dangerous Drugs Act*;

"exempt medical practitioner" means a medical practitioner within the class referred to in Schedule 1.

NORTHERN TERRITORY OF AUSTRALIA

Poisons and Dangerous Drugs Act

DECLARATION OF EXEMPTION FROM REQUIREMENT
TO HOLD AUTHORISATION TO SUPPLY
RESTRICTED SCHEDULE 8 SUBSTANCES

I, TARUN STEPHEN WEERAMANTHRI, the Chief Health Officer, pursuant to section 31P of the *Poisons and Dangerous Drugs Act* and with reference to section 8 of the *Interpretation Act*, exempt the classes of medical practitioners specified in Schedule 1 from the requirement to hold an authorisation under section 31G of the *Poisons and Dangerous Drugs Act* to supply methadone or buprenorphine (restricted Schedule 8 substances), subject to the conditions in Schedule 2.

Dated

13th January

2005.

Chief Health Officer

SCHEDULE 1

EXEMPT CLASSES OF MEDICAL PRACTITIONERS

Hospital specialists.

Hospital senior registrars

SCHEDULE 2
CONDITIONS OF EXEMPTION
HOSPITAL SPECIALISTS AND SENIOR REGISTRARS

1. A medical practitioner within a class referred to in Schedule 1 ("the exempt medical practitioner") may supply methadone or buprenorphine only to a patient in the care of the exempt medical practitioner.
 2. If the patient is a current client of a medical practitioner who holds an authorisation under section 31G of the *Poisons and Dangerous Drugs Act* to supply methadone or buprenorphine to the client, the exempt medical practitioner may supply the methadone or buprenorphine to the patient only if it is impossible for the patient's current medical practitioner to review, and supply the methadone or buprenorphine to, the patient.
 3. The exempt medical practitioner may supply the methadone or buprenorphine to the patient only after the exempt medical practitioner has obtained the advice of a clinician employed by the Agency administering the *Poisons and Dangerous Drugs Act* –
 - (a) in the Alcohol and Other Drugs Service or Alcohol and Other Drugs Service Central Australia; or
 - (b) in the opiate pharmacotherapy program of the Agency.
 4. The exempt medical practitioner must record the following particulars in the patient's case notes:
 - (a) the name of the clinician who gave advice to the exempt medical practitioner, the nature of the advice and the date and time the advice was given;
 - (b) the name of the exempt medical practitioner supplying the methadone or buprenorphine and the date and time of the supply.
 5. The exempt medical practitioner may supply the methadone or buprenorphine to an outpatient of the hospital for a maximum of 3 days.
 6. The exempt medical practitioner may supply the methadone or buprenorphine to an inpatient of the hospital for the period the exempt medical practitioner considers appropriate.
-
-

NORTHERN TERRITORY OF AUSTRALIA

Poisons and Dangerous Drugs Act

DECLARATION OF EXEMPTION FROM REQUIREMENT
TO HOLD AUTHORISATION TO SUPPLY
RESTRICTED SCHEDULE 8 SUBSTANCES

I, TARUN STEPHEN WEERAMANTHRI, the Chief Health Officer, pursuant to section 31P of the *Poisons and Dangerous Drugs Act* and with reference to section 8 of the *Interpretation Act*, exempt the class of medical practitioners specified in Schedule 1 from the requirement to hold an authorisation under section 31G of the *Poisons and Dangerous Drugs Act* to supply methadone or buprenorphine (restricted Schedule 8 substances), subject to the conditions in Schedule 2.

Dated

13th January

2005.

Chief Health Officer

SCHEDULE 1

EXEMPT CLASS OF MEDICAL PRACTITIONERS

Locums of general practitioners who hold an authorisation under section 31G of the *Poisons and Dangerous Drugs Act*

SCHEDULE 2

CONDITIONS OF EXEMPTION LOCUMS OF AUTHORISED GENERAL PRACTITIONERS

1. A member of the exempt class referred to in Schedule 1 ("the locum") may supply methadone or buprenorphine for a maximum of one month from the date on which the locum begins working for the medical practitioner who hold an authorisation under section 31G of the Act ("the authorised general practitioner").
 2. The locum may supply methadone or buprenorphine only to a patient in respect of whom the authorised general practitioner holds an authorisation under section 31G of the Act.
 3. The locum must not change the substance usually supplied by the authorised general practitioner to a patient or the dose of the substance supplied, whether administered at the place where the locum is working or self-administered by the patient at another place, except in accordance with the following:
 - (a) if the locum considers a change in the supply is absolutely necessary, the locum must seek the advice of a clinician employed by the Agency administering the Act -
 - (i) in the Alcohol and Other Drugs Service or Alcohol and Other Drugs Service Central Australia; or
 - (ii) in the opiate pharmacotherapy program of the Agency;
 - (b) the locum may change the supply only on the advice of a clinician referred to in paragraph (a);
 - (c) the locum must record in the patient's case notes the name of the clinician who gave the advice to the locum, the nature of the advice and the date and time the advice was given.
-
-

NORTHERN TERRITORY OF AUSTRALIA

Poisons and Dangerous Drugs Act

DECLARATION OF EXEMPTION FROM REQUIREMENT
TO HOLD AUTHORISATION TO SUPPLY
RESTRICTED SCHEDULE 8 SUBSTANCES

I, TARUN STEPHEN WEERAMANTHRI, the Chief Health Officer, pursuant to section 31P of the *Poisons and Dangerous Drugs Act* and with reference to section 8 of the *Interpretation Act*, exempt the classes of medical practitioners specified in Schedule 1 from the requirement to hold an authorisation under section 31G of the *Poisons and Dangerous Drugs Act* to supply dexamphetamine or methylphenidate (restricted Schedule 8 substances), subject to the conditions in Schedule 2.

Dated

13th January

2005.

Chief Health Officer

SCHEDULE 1

EXEMPT CLASSES OF MEDICAL PRACTITIONERS

Medical practitioners who are recognised in the Territory as specialist
paediatricians

Registrars in training of medical practitioners who are recognised in the
Territory as specialist paediatricians

SCHEDULE 2

CONDITIONS OF EXEMPTION SPECIALIST PAEDIATRICIANS AND THEIR REGISTRARS IN TRAINING

1. A medical practitioner within the exempt class referred to in Schedule 1 ("exempt medical practitioner") may supply dexamphetamine or methylphenidate to a particular patient of the exempt medical practitioner for a maximum of 30 days.
 2. The 30 days of supply includes all periods of supply of dexamphetamine or methylphenidate to the particular patient that, in aggregate during the preceding 12 months, total 30 days, whether the supply is by one or more exempt medical practitioner.
-
-